Hypertriglyceridemia

3,646views

Hypertriglyceridemia

Joana

Joana

Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Diabetes insipidus
Diabetes mellitus
Hypoglycemics: Insulin secretagogues
Thyroid cancer
Thyroid nodules and thyroid cancer: Clinical
Diabetes mellitus: Clinical
Hypertriglyceridemia
Anatomy of the thyroid and parathyroid glands
Insulins
Diabetes mellitus
Adrenal masses: Pathology review
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Pathology review
Primary adrenal insufficiency
Congenital adrenal hyperplasia
Adrenal gland histology
Adrenal masses: Pathology review
Adrenal masses and tumors: Clinical
Esophageal cancer
Gastric cancer
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Peptic ulcers and stomach cancer: Clinical
Colorectal cancer
Colorectal cancer: Clinical
Metaplasia and dysplasia
Diabetic nephropathy
Benign liver tumors
Hepatocellular carcinoma
Peptic ulcer
Peptic ulcer
Helicobacter pylori
Cirrhosis
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Gallbladder carcinoma
Wilson disease
Pancreatic cancer
Carcinoid syndrome
Acromegaly
Viral hepatitis
Hyperthyroidism: Clinical
Alcohol-associated liver disease
Non-alcoholic fatty liver disease
Pituitary adenoma
Non-steroidal anti-inflammatory drugs
Diarrhea: Clinical
Metabolic acidosis
Metabolic alkalosis
Ulcerative colitis
Crohn disease
Respiratory acidosis
Nephrotic syndromes: Pathology review
Goodpasture syndrome
Nephritic syndromes: Pathology review
Respiratory alkalosis
Cholestatic liver disease
Laxatives and cathartics
Polycystic ovary syndrome
MEN syndromes: Clinical
Autoimmune polyglandular syndrome type 1 (NORD)
Type I and type II errors
Gastroesophageal reflux disease (GERD)
Celiac disease
Polycystic kidney disease
Chronic kidney disease
Acute kidney injury: Clinical
IgA nephropathy (NORD)
Focal segmental glomerulosclerosis (NORD)
Minimal change disease
Chronic kidney disease: Clinical
Cytomegalovirus infection after transplant (NORD)
Hyperkalemia: Clinical
Atherosclerosis and arteriosclerosis: Pathology review
Portal hypertension
Cirrhosis: Clinical
Hypercholesterolemia: Clinical
Gallbladder histology
Chronic cholecystitis
Gout
Gout and pseudogout: Pathology review
Lesch-Nyhan syndrome
Macrocytic anemia: Pathology review
Alpha-thalassemia
Beta-thalassemia
Anemia: Clinical
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Aplastic anemia
Von Willebrand disease
Acute leukemia
Lung cancer: Clinical
Lung cancer
Breast cancer: Clinical
Breast cancer
Monoclonal antibodies
Atrioventricular block
Heart blocks: Pathology review
Abnormal heart sounds
Heart failure
Pulmonary embolism
Pulmonary edema
Pulmonary valve disease
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Innate immune system
Introduction to the immune system
Complement system
T-cell development
B-cell development
MHC class I and MHC class II molecules
T-cell activation
B-cell activation, differentiation, and contraction
Antibody classes
Somatic hypermutation and affinity maturation
VDJ rearrangement
Contracting the immune response and peripheral tolerance
B- and T-cell memory
Vaccinations
Type I hypersensitivity
Food allergy
Anaphylaxis
Asthma
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Graft-versus-host disease
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
ELISA (Enzyme-linked immunosorbent assay)
Gel electrophoresis and genetic testing
Fluorescence in situ hybridization
Precipitation reactions
Isolated primary immunoglobulin M deficiency
Selective immunoglobulin A deficiency
Blood groups and transfusions
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE): Pathology review
Systemic lupus erythematosus (SLE): Clinical
Chronic granulomatous disease
Complement deficiency
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
DiGeorge syndrome
X-linked agammaglobulinemia
Hyper IgM syndrome
Leukocyte adhesion deficiency
Immunodeficiencies: Clinical
HIV (AIDS)
Cell-cell junctions
Hashimoto thyroiditis
Wiskott-Aldrich syndrome
Food allergies and EpiPens: Information for patients and families (The Primary School)
Vaccinations: Clinical
Blood products and transfusion: Clinical
Hypersensitivity skin reactions: Clinical
Shock: Clinical
Rheumatic heart disease
Immune thrombocytopenia
Rheumatoid arthritis
Rheumatoid arthritis: Clinical
Multiple sclerosis

Transcript

Watch video only

With Hypertriglyceridemia, hyper means high, -emia refers to blood levels, and triglycerides are the most abundant fatty molecules in an organism.

So, hypertriglyceridemia is when there’s excess triglycerides in the blood.

Specifically, hypertriglyceridemia is when there are more than 150 mg of triglycerides per deciliter of blood.

Triglycerides can be deposited in subcutaneous tissue and around organs and function as energy storage in the body.

We can either get triglycerides from our diet, which are called exogenous triglycerides; or our liver can synthesize them from other molecules, in which case they’re called endogenous triglycerides.

Now, exogenous triglycerides are first absorbed in the small intestine, and then they undergo a series of changes in order to be transported and deposited in the body.

So, after triglycerides are absorbed, they enter the intestinal mucosal cells, inside of which they’re coupled with various apolipoproteins and phospholipids to create chylomicrons, which are one type of lipoprotein.

Lipoproteins are made up of lipids (like triglycerides or cholesterol) or phospholipids and proteins (like apolipoproteins CII, CIII, or E).

The main job of lipoproteins is to carry insoluble molecules, like triglycerides, from the intestines to the circulation.

That's because, normally, triglycerides are insoluble in liquid environments like blood.

Now, the newly created chylomicrons enter the bloodstream and bind to the wall of capillaries in adipose and skeletal muscle tissue.

At the binding site, they interact with the lipoprotein lipase enzyme leading to the breakdown of the triglyceride core and liberation of free fatty acids directly into the adipocytes or skeletal muscle cell, where they’re either stored or used for energy.

After triglycerides leave the chylomicron, what’s left is called a remnant chylomicron.

Remnant chylomicrons are high in cholesterol esters and they’re cleared from circulation by the liver when the apolipoprotein E binds to Apo-B100/E receptor on the hepatic cell membrane.

The remnant chylomicrons are then degraded by acid hydrolases to a mixture of amino acids, free fatty acids, and cholesterol.

Now let’s switch gears and look at how endogenous triglycerides are synthesized.

First, the liver makes another type of lipoproteins called very low-density lipoproteins, or VLDL.

The fatty acids are either synthesized from scratch from carbohydrates or released from adipose tissue.

Then, the liver exports the triglyceride-rich VLDL molecules into the bloodstream, which carries them to muscle and adipose cells.

Here, VLDL are cleaved by lipoprotein lipase to intermediate-density lipoproteins(IDL), also called VLDL remnants.

The IDL are further metabolized to low-density lipoproteins, LDL, and are released into the bloodstream, which are taken up by the LDL receptor in numerous tissues including the liver.

Ok, so hypertriglyceridemia can result from anomalies in either the exogenous or the endogenous pathways, but in either case, excessive triglyceride levels accumulate in the body.

Depending on where they accumulate, they may cause complications like atherosclerosis and acute pancreatitis.

Now, atherosclerosis can occur via a pathway that involves an endothelial dysfunction.

This dysfunction allows small triglycerides remnants to reach the intimal layer where they get taken up by the macrophages, leading to the formation of foam cells.

Foam cells promote fatty streak formation: the precursor of atherosclerotic plaque.

Acute pancreatitis, on the other hand, occurs due to high concentrations of large chylomicrons in the blood which can obstruct the capillaries leading to ischemia of the pancreas.

Now, hypertriglyceridemia is commonly classified as either primary (or familial) hypertriglyceridemia and secondary (or acquired) hypertriglyceridemia.

Secondary causes are more common, and they may be associated with obesity, diabetes mellitus, high carbohydrate diets, hypothyroidism, or increased alcohol intake, all of which impact lipid metabolism.

Alright, so three of the most common secondary forms of hypertriglyceridemia are obesity, diabetes mellitus type 1 and 2, and high carbohydrate diets.

With obesity-associated hypertriglyceridemia, there is a hepatic overproduction of VLDL and decreased circulating triglycerides breakdown.

On the other hand, in uncontrolled diabetes mellitus, both type 1 and type 2, hypertriglyceridemia is associated with a lipoprotein lipase that is either ineffective or less effective than normal.

Finally, high-carbohydrate diets, where carbohydrates make up more than 60% of the total caloric intake, lead to increased carbohydrate breakdown and increased production of free fatty acids as a consequence.

The excess free fatty acids can be used to synthesize more triglycerides, therefore causing hypertriglyceridemia

Key Takeaways

Hypertriglyceridemia is a condition characterized by high levels of triglycerides in the blood. If individuals' serum triglyceride concentrations are above 150 mg/dL, they are considered hypertriglyceridemia. High levels of triglycerides in the blood are associated with a high risk of developing heart disease, stroke, and other health problems. There are many different causes of hypertriglyceridemia, including genetics, obesity, eating too much processed or unhealthy foods, not getting enough exercise, smoking cigarettes, and drinking alcohol.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Hypertriglyceridemia: its etiology, effects and treatment" Canadian Medical Association Journal (2007)
  7. "Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline" The Journal of Clinical Endocrinology & Metabolism (2012)
  8. "Hypertriglyceridemic Pancreatitis: Presentation and Management" The American Journal of Gastroenterology (2009)